New data on the effectiveness of Tadalafil alone and in combination with NeyroDoz® in treating erectile dysfunction associated with secondary premature ejaculation
- Authors: Akhvlediani N.D1, Matyukhov I.P1
-
Affiliations:
- Research Institute for Uronephrology and Human Reproductive Health, I.M. Sechenov First MSMU
- Issue: No 5 (2016)
- Pages: 52-56
- Section: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/286546
- ID: 286546
Cite item
Open Access
Access granted
Abstract
Aim To compare the effectiveness of the phosphodiesterase type 5 inhibitor (PDE-5i) tadalafil alone and in combination with a biologically active dietary supplement (BADS) NeyroDoz®, containing the precursors of serotonin in patients with erectile dysfunction (ED) associated with secondary premature ejaculation (SPE). Material and methods 105 patients (mean age 36.2+9.1 years) with concomitant ED and SPE were included in a prospective study and divided into 2 groups. The patients of group 1 (n=47) received PDE-5i 5 mg daily for 1 month. In patients of group 2 (n=58) PDE-5i was co-administered with BADS 2 capsules twice daily. Treatment efficacy was evaluated using «Criteria for premature ejaculation” (CriPE) and IIEF-5 questionnaires at baseline and on completion of the treatment course. Besides, a polymorphism in the serotonin transporter gene (5-HTTLPR) was tested. Results The treatment was effective in 35 (74.5%) and 48 (82.7%) patients of group 1 and 2, respectively (p<0.0001) with similar statistically significant (p<0.001) improvement in erectile function. According to CriPE scores, 6.4, 8.5, 23.4, 10.6 and 12.8% patients of group 1 and 10.3, 1.7, 40.0, 25.9, 10.3 and 31.0% patients of group 2 with LaLa, LaLg, LgLg, Sla, SLg, SS genotypes were rendered free of SPE, respectively. Conclusion Treating ED-associated SPE with the combination of serotonin precursors and tadalafil can better improve ejaculatory function recovery compared with PDE-5i monotherapy.
Keywords
Full Text
About the authors
N. D Akhvlediani
Research Institute for Uronephrology and Human Reproductive Health, I.M. Sechenov First MSMU
Email: nikandro@mail.ru
Dr.Med.Sci., Prof. at the Department of Urology
I. P Matyukhov
Research Institute for Uronephrology and Human Reproductive Health, I.M. Sechenov First MSMU
References
- Hatzimouratidis K., Giuliano F., Moncada I., Muneer A., Salonia A., Verze P. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. EAU. 2016;24-31.
- Corona G., Rastrelli G., Limoncin E., Sforza A., Jannini E.A., Maggi M. Interplay Between Premature Ejaculation and Erectile Dysfunction: A Systematic Review and Meta-Analysis. J. Sex Med. 2015;12(12):2291-300. doi: 10.1111/jsm.13041.
- Глыбочко П.В., Аляев Ю.Г., Ахвледиани Н.Д. Терапия вторичного преждевременного семяизвержения, обусловленного эректильной дисфункцией. Врач. 2011;7:46-48
- Zhu L., Mi Y., You X., Wu S., Shao H., Dai F., Peng T., Qin F., Feng N. A meta-analysis of the effects of the 5-hydroxytryptamine transporter gene-linked promoter region polymorphism on susceptibility to lifelong premature ejaculation. PLoS One. 2013;8(1):e54994. doi: 10.1371/journal.pone.0054994.
- Dresser M.J., Desai D., Gidwani S., Seftel A.D., Modi N.B. Dapoxetine, a novel treatment for premature ejaculation, does not have pharmacokinetic interactions with phosphodiesterase-5 inhibitors. Int J. Impot Res. 2006;18(1): 104-10. doi: 10.1038/ sj.ijir.3901420.
- Камалов А.А., Абоян И.А., Ситдыкова М.Э., Цуканов А.Ю., Теодорович О.В., Медведев В.Л., Комяков Б.К., Журавлев В.Н., Новиков А.И., Еркович А.А., Охоботов Д.А., Карпов В.К., Зубков А.Ю. Терапия ускоренного семяиз вержения биологически активной добавкой к пище НейроДоз: результаты мультицентрового клинического нерандомизированного исследования. Урология. 2013;7:37-42
- Аляев Ю.Г., Ахвледиани Н.Д. Сравнение эффективности селективной пенильной денервации и циркумцизио при преждевременной эякуляции. Урология. 2016;1(1):60-64
Supplementary files
